Analisi di Budget Impact di Ticagrelor nel Trattamento di Prevenzione in Pazienti con Sindrome Coronarica Acuta

Perna, Gian Piero; Ravasio, Roberto; Ricciardelli, Antonio

doi:10.5301/grhta.5000255

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Net ex-factory prices were considered when estimating the cost of the treatments: a) for anakinra, the official net ex-factory prices (including mandatory discounts: −5%, −5%) [ 24 ]; b) for canakinumab, which at the time of the analysis was subject to a payback agreement, there was a −5% discount on the ex-factory price, thus an additional −5% discount was considered, in line with previous Italian studies [ 33 , 34 ]. Therefore, the base case analysis was carried out considering a price of € 28.47 for a 100-mg syringe of anakinra and € 9,927.50 for a 150-mg vial of canakinumab.…”

Section: Methodsmentioning

confidence: 99%

Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy

Aiello¹,

Mariano²,

Prada³

et al. 2023

Journal of Market Access & Health Policy

View full text Add to dashboard Cite

Introduction: Familial Mediterranean Fever (FMF) is a hereditary autoinflammatory disease that significantly reduces occupational productivity and quality-of-life in affected patients. Italy has an estimated FMF prevalence of 1 in 60,000 people. While colchicine is the primary treatment for FMF, biologics are administered to intolerant and non-responder patients. Anakinra and canakinumab are the only biologics approved and reimbursed for FMF in Italy. Both medicines have demonstrated efficacy in FMF patients yet differ in treatment costs. This study aimed to perform a budget impact analysis (BIA) following anakinra’s reimbursement for FMF treatment, considering pharmaceutical costs from the Italian National Healthcare Service (NHS) perspective. Methods: A ‘Reference scenario’ (all patients treated with canakinumab) was compared to an ‘Alternative scenario’, with increased anakinra market shares. The target population was estimated based on the Italian population, epidemiological and market research data. Drugs costs were estimated based on Summary of Product Characteristics and net ex-factory prices. Sensitivity analyses were implemented to test results’ robustness. Results:The base case analysis showed an overall cumulative expenditure of €30,586,628 for ‘Reference scenario’ and € 16,465,548 for ‘Alternative scenario’. A cumulative savings of €14,121,080 (46.2%) was calculated over 3 years as a result of the reimbursement and increasing uptake of anakinra. The sensitivity analyses, even considering a discount of 50% for canakinumab, confirmed the base case results. Conclusions: Anakinra’s introduction, in FMF treatment, provides a financially sustainable option for Italian patients, with savings increasing according to greater use of anakinra.

show abstract

Section: Methodsmentioning

confidence: 99%

Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy

Aiello¹,

Mariano²,

Prada³

et al. 2023

Journal of Market Access & Health Policy

View full text Add to dashboard Cite

show abstract

“…We used actual net public prices, according to the Italian market data, 18 for both COPD treatments and concomitant therapies (such as those used to alleviate SAEs); an additional discount of 5% was considered for drugs to which a payback agreement applies, in line with a previous Italian study. 32 To estimate the actual drug dose a compliance rate of 40% (i.e. the percentage of drugs' daily dose taken by patients), according to Italian market data, 29 was applied to the recommended posology of each COPD drug.…”

Section: Costsmentioning

confidence: 99%

Budget impact model of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease in Italy based on the FLAME study

Aiello

Ritrovato

Pitotti

2018

Global & Regional Health Technology Assessment

View full text Add to dashboard Cite

We aimed to estimate the 3-year budget impact of replacing salmeterol/fluticasone with indacaterol/ glycopyrronium for the treatment of chronic obstructive pulmonary disease patients in Italy. Methods: The budget impact model included patients with moderate, severe, and very severe chronic obstructive pulmonary disease and was developed using data from the FLAME study. The budget impact model considered direct medical costs from the National Healthcare System perspective over a 3-year time-horizon. Costs of drugs, adverse events, and exacerbations were estimated using public net prices for drugs and national (inpatient/outpatient) tariffs for patient management. Data on adverse events and exacerbations were derived from FLAME and other clinical trials. The model assumed an increasing uptake of indacaterol/glycopyrronium, substituting it for salmeterol/fluticasone. Two sensitivity analyses were conducted. In the first, every long-acting muscarinic antagonist/inhaled corticosteroid switch to indacaterol/glycopyrronium; in the second, drugs compliance varies from 20% to 60%. Results: The target population was estimated at 572,788 patients in the first year, increasing to 585,491 in the third year. The alternative treatment pattern, with a higher indacaterol/glycopyrronium uptake, was associated with a total cost of €1.69 billion over 3 years, while the total costs in the current treatment pattern amounted to €1.71 billion. Thus, increasing indacaterol/glycopyrronium use provided total savings of €17.3 million over 3 years. Sensitivity analysis confirmed robustness of the results. Conclusion: Increasing the uptake of indacaterol/glycopyrronium was estimated to be cost-saving for the Italian National Healthcare System, both when drug-related expenditures and total costs were considered. Savings increased with the number of patients switching to indacaterol/glycopyrronium.

show abstract

Analisi di Budget Impact di Ticagrelor nel Trattamento di Prevenzione in Pazienti con Sindrome Coronarica Acuta

Cited by 2 publications

References 10 publications

Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy

Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy

Budget impact model of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease in Italy based on the FLAME study

Contact Info

Product

Resources

About